Illumina’s MiSeqDx instrument and MiSeqDx Universal Kit, granted de novo approval, allow clinicians to “develop and validate sequencing of any part of a patient’s genome,” FDA says.

Illumina’s MiSeqDx instrument and MiSeqDx Universal Kit, granted de novo approval, allow clinicians to “develop and validate sequencing of any part of a patient’s genome,” FDA says.

Invacare reports its earnings are hindered by an FDA consent decree, but management hopes to be released from the agreement soon. The American Hospital Association signs onto a letter to Congress calling for a crackdown on so-called “patent trolls.” More news in brief

A Battelle report on the impact of genomics on the U.S. economy found that research on human genome sequencing led to $65 billion in economic output in 2012, and contributed $31 billion toward the 2012 gross domestic product.